# A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

> **NCT02937675** · PHASE1,PHASE2 · TERMINATED · sponsor: **Effector Therapeutics** · enrollment: 28 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Tomivosertib (eFT-508)

## Key facts

- **NCT ID:** NCT02937675
- **Lead sponsor:** Effector Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-08
- **Primary completion:** 2018-11-12
- **Final completion:** 2019-04-04
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** patient recruitment
- **Last updated:** 2020-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937675, "A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02937675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*